6 results about "Iodixanol" patented technology

The invention discloses a single-cell suspension purification method capable of maintaining representativeness of a cell population and a kit, and belongs to the technical field of single-cell separation. The method comprises the following steps that a cell sample to be separated and purified is resuspended in a centrifugal container through a reagent B, then a reagent A is added and evenly mixed, the adding amount of the reagent A and the reagent B is adjusted so that the density of the suspension can be 1.08-1.15 g / ml, the reagent A is an aqueous solution containing iodixanol, and the reagent B is a DMEM culture medium containing 1-10% of FBS; and slowly laying PBS on the upper layer of the suspension, centrifuging, collecting living cells of an interface layer, washing the obtained living cells, and re-suspending. According to the scheme, the single-cell suspension for single-cell library construction can be purified under the conditions of low equipment requirement, low cost and mild conditions, the cell population representativeness of a sample can be reserved to the maximum extent while dead cells are removed, and no adverse effect is generated on the single-cell library construction process.

The invention discloses a method for determining a palladium element impurity in iodixanol by using an iridium element as an internal standard element. The method is good in specificity and high in sensitivity, trace residues of palladium (Pd) element impurities in iodixanol can be effectively detected, interference of sample treatment on impurity detection is effectively reduced, it is ensured that the palladium (Pd) element impurities can be accurately quantified, and the requirements of laws and regulations for residue detection of the palladium (Pd) element impurities are met.

The application discloses a contrast agent for enhancing the effect of ELCA volume reduction, and belongs to the field of medical reagents, and particularly relates to a contrast agent which comprises a heparin-based compound and a contrast agent, wherein the heparin-based compound comprises heparin, and the content of the heparin-based compound in the contrast agent is 2-64 mu g / mL. The contrast agent comprises at least one of iopromide and iodixanol. The heparin-based compound further comprises a heparin derivative, and the heparin derivative is prepared by subjecting heparin to oxidation and then to reaction with a derivatizing agent. The derivatizing agent comprises L-alanyl-L-proline methyl ester hydrochloride. The application is a contrast agent which can be combined with ELCA, enhances the effect of ELCA volume reduction, has a good effect on blood vessel plaque erosion, and has high shock wave pressure when combined with excimer laser.

The application relates to the field of transmission electron microscopes, in particular to an exosome transmission electron microscope sample preparation method, which comprises the following steps: 1) arranging exosomes in an iodixanol-containing buffer system to prepare a sample solution; 2) adsorbing the sample solution in step 1) on a carrier to prepare a pre-electron microscope sample; and 3) removing the solution on the surface of the pre-electron microscope sample in step 2), performing rinsing and negative staining, and then drying to prepare a transmission electron microscope sample. The exosome electron microscope sample prepared by the method does not collapse, presents a negative staining effect, a clean background, a clear and complete exosome contour imaging effect, can obtain an exosome image with a complete structure and without collapse, can be automatically counted by using image processing software, and makes exosome particle size counting more accurate and convenient.

This invention relates to a method for preparing iodine-based nanocontrast agents. Based on the specific and efficient esterification reaction between fluorinated phenylboronic acid groups and ortho-dihydroxy structures, an amphiphilic block polymer containing fluorinated phenylboronic acid groups is co-crosslinked with water-soluble nonionic polyhydroxy iodine-based contrast agents such as iohexol, iodofol, iodixanol, iopromide, iodomeprazole, iodiphenol, iodpentol, and iotram. No chemical modification of the iodine-based contrast agents is required. The water-soluble nonionic polyhydroxy iodine-based contrast agents can be easily and efficiently nano-sized through the phenylboronic acid esterification crosslinking reaction to obtain iodine-based nanocontrast agents. This invention has the advantages of a simple and controllable preparation process, mild reaction conditions, inexpensive and readily available raw materials, and no toxic byproducts. Furthermore, the prepared iodine-based nanocontrast agents exhibit good dispersion stability and excellent imaging contrast performance. When the concentration of the iodine-based nanocontrast agent reaches 120 mg / mL, the CT value reaches as high as 1150 HU.

This invention belongs to the field of biomedicine and pharmaceutical technology, and discloses a liposome delivery system for thymus-targeted imaging and / or treatment, its preparation method, and applications. The delivery system uses liposomes as carriers and modifies the carriers with terminal carboxyl-modified polyethylene glycol-phospholipid derivatives (DSPE-PEG-COOH) to form functionalized liposome structures. It can efficiently encapsulate iodine contrast agents (e.g., iodixanol) and covalently couple CD205 antibodies to the liposome surface, thereby achieving active targeting of thymic epithelial cells. This system can enhance the specificity and stability of thymus CT imaging. Furthermore, this delivery platform can also be used to load various therapeutic drugs (such as hydroxyflutamide), achieving local drug accumulation in the thymus region, enhancing the intervention effect while effectively reducing systemic toxicity.